Pulmatrix is at the forefront of developing innovative pulmonary-delivered therapeutics, leveraging its proprietary iSPERSE™ technology. This platform is designed to optimize the dispersion of inhaled therapeutic particles throughout the lungs, enhancing both efficacy and safety in treatment. Unlike conventional dry powder technologies that often rely on lactose blending or low-density particles, iSPERSE™ utilizes small, dense, and dispersible particles to ensure efficient delivery. This advancement allows for a new generation of therapies that can significantly improve patient outcomes for both respiratory and non-respiratory diseases.

The company is currently advancing several products in its pipeline, including PUR3100, PUR1800, and PUR1900, each targeting specific medical conditions. PUR3100 is an inhaled formulation of dihydroergotamine aimed at providing rapid relief for acute migraines, while PUR1800 is a narrow-spectrum kinase inhibitor being developed for acute exacerbations in chronic obstructive pulmonary disease (AECOPD). Additionally, PUR1900, an inhaled formulation of itraconazole, is designed to treat allergic bronchopulmonary aspergillosis (ABPA) with significantly improved lung exposure and reduced plasma exposure compared to existing oral formulations. Through these developments, Pulmatrix aims to address critical unmet needs in patient care and enhance treatment options for serious pulmonary diseases.

United States

PULMATRIX is committed to the development and commercialization of novel and transformational medicines for patients all over the world, using our proprietary iSPERSE™ technology to optimally deliver both respiratory and non-respiratory therapies via the respiratory system.

Pulmatrix

Company Details